Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of social ...
The Company is currently developing CYB003, a proprietary deuterated psilocin program, about to enter Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004 ... Company ...
Social media use in teenagers is strongly correlated to higher anxiety and depression ... Teenage girls are the most likely to be in treatment, with about a fifth of 16- and 17-year-old girls ...
The national survey, conducted in August of 2024, took place online and over the phone and included 1,006 American adults. Results showed younger adults are more likely to believe they are undiagnosed ...